The Molecular Biology Society of JapanThe 45th Annual Meeting of the Molecular Biology Society of Japan Cooperated by the Biophysical Society of Japan

The latest information on genetic disease research will be presented. Not only the new product Illumina® Complete Long Reads, a long read technology announced this year, but also on data analysis solutions such as DRAGEN™ will be discussed. Please stop by!

<Lecture 1: Aiming to Contribute to Medicine through Optogenetics: Research on Rhodopsin Responsive to Violet to Near-Infrared Light>
Optogenetics is a technology to manipulate biological functions by expressing photoreceptor proteins such as rhodopsin in specific cells. By developing photoreceptor molecules with various characteristics, this technology can be applied to the elucidation of all kinds of biological phenomena. In this presentation, we will introduce an example of neural activation by rhodopsin, a channel that absorbs violet light and has high calcium permeability, and the molecular mechanism of rhodopsin, an enzyme that absorbs near-infrared light and shows cyclase activity, recently discovered by our research group.

<Lecture 2: Overview of Library Construction Service-1>
Now that it is relatively inexpensive to decipher genome sequences and analyze comprehensive gene expression profiles by next-generation sequencing, Vector Builder offers a custom library construction service to help you screen your target genes from a large number of candidate genes. We will introduce how our high-quality custom libraries are constructed, their convenience, and examples of their use.

<Lecture 3: Overview of Library Construction Service-2>
Vector Builder proposes libraries suitable for users' needs. The types of libraries vary widely, including shRNA, gRNA, CRISPRa/CRISPRi, and random peptide libraries. Library construction costs tend to be expensive, so designing cost-effective libraries is essential. We will introduce the design tips for high quality custom libraries that provide reliable screening results.

<Lecture 4: IVT mRNA part 1: Basics of IVT mRNA design and production>
Recent breakthroughs with in vitro transcribed mRNA technology have allowed it to emerge as a promising solution for therapeutic obstacles. The launch of the two mRNA-based SARS-CoV-2 vaccines demonstrated key advantages of the technology including rapid development, easy scaleup of production, and robust in vivo expression. The stability, function, and immunogenicity of a given mRNA is affected by many intrinsic factors including untranslated regions, coding sequence, polyA tail, production conditions (modified nucleotide incorporation, purification), etc. VectorBuilder Inc. generates mRNA, and its efficacy has been thoroughly validated both in vitro and in vivo. We provide one-stop service from design to production to help researchers develop novel therapeutics using this exciting technology.

The latest information on microbiology research will be presented. We will introduce comprehensive analyses that take advantage of the cost benefits of NextSeq™ 1000/2000, such as metatranscriptome analysis using the new Ribo-Zero™ Plus Microbiome Depletion Kit. Please stop by!

<Lecture 1: Designing Sustainable Vectors for Translational Research>
VectorBuilder offers of multiple production methods to help you decide which process will best meet your needs. If you are not ready for clinical GMP viral vector manufacturing, still you must choose right materials at your early development. At this Technical seminar, I will discuss the importance of an effective design strategy by working backwards from end-goal commercialization.

<Lecture 2: Let's use the Vector Builder to your advantage! Part 1: shRNA gene knockdown vector design>
We have a platform that allows you to easily design U6 and miR30 based shRNA expression vectors. In this seminar, we will explain (1) how to design gene knockdown vectors using our platform, (2) the process from quotation to order, (3) useful technical information we have made available, and (4) other tips.

<Lecture 3: Analysis of various AAVs using adeno-associated virus (AAV) receptor-immobilized columns (tentative)>
Adeno-associated virus (AAV) vectors are widely used as gene therapeutic agents. The authors immobilized the AAV receptor (AAVR), which contributes to AAV infection, on a gel, developed an affinity chromatography column, and chromatographically analyzed various types of AAV. The elution times of AAV produced by us and VectorBuilder were identical for each serotype. In addition, AAV4, which does not have AAVR-dependent infection, was passed through the chromatogram, suggesting that analysis close to the intracellular environment is possible.

<Lecture 4: IVT mRNA part 2: Applications of IVT mRNA>
Recent breakthroughs with in vitro transcribed mRNA technology have allowed it to emerge as a promising solution for therapeutic obstacles. The launch of the two mRNA-based SARS-CoV-2 vaccines demonstrated key advantages of the technology including rapid development, easy scaleup of production, and robust in vivo expression. The stability, function, and immunogenicity of a given mRNA is affected by many intrinsic factors including untranslated regions, coding sequence, polyA tail, production conditions (modified nucleotide incorporation, purification), etc. VectorBuilder Inc. generates mRNA, and its efficacy has been thoroughly validated both in vitro and in vivo. We provide one-stop service from design to production to help researchers develop novel therapeutics using this exciting technology.

The latest information on cancer research will be provided. We will present not only recently released sequencers such as NovaSeq™ X series, but also library preparation technology as preprocessing and the latest data analysis technology. Please stop by!

<Lecture 1: AAV Capsid Evolution and Biodistribution>
VectorBuilder offers one-on-one CRO solutions. In this technical seminar, I discuss about existing problems and limitations on AAV in terms of gene therapy. I will introduce solutions in our CRO service lineups, AAV capsid evolution and AAV Biodistribution. The knowledge base generation which required for long term strategies supports research and discoveries translate clinical production.

<Lecture 2: Let's use the Vector Builder to our advantage! Part 2: Tet-inducible gene expression vector design>
We have a platform that allows you to easily design Tet-inducible gene expression vectors. In this seminar, we will explain (1) how to design gene expression vectors using our platform, (2) the flow from quotation to order, (3) useful technical information we have made available, and (4) other tips.

<Lecture 3: Keys designing IVT mRNA vectors>
Based on extensive design and production experience, VectorBuilder can support researchers for in vitro transcription (IVT) vector design, vector cloning, in vitro mRNA synthesis, mRNA-LNP production, and in vitro/in vivo functional testing to accelerate the development of mRNA-based vaccines and gene therapy. In this lecture, tips for IVT mRNA vector design will be explained with practical examples.

<Lecture 4: IVT mRNA part 3: VectorBuilder's one-stop solution for mRNA development>
Recent breakthroughs with in vitro transcribed mRNA technology have allowed it to emerge as a promising solution for therapeutic obstacles. The launch of the two mRNA-based SARS-CoV-2 vaccines demonstrated key advantages of the technology including rapid development, easy scaleup of production, and robust in vivo expression. The stability, function, and immunogenicity of a given mRNA is affected by many intrinsic factors including untranslated regions, coding sequence, polyA tail, production conditions (modified nucleotide incorporation, purification), etc. VectorBuilder Inc. generates mRNA, and its efficacy has been thoroughly validated both in vitro and in vivo. We provide one-stop service from design to production to help researchers develop novel therapeutics using this exciting technology.